Akari Therapeutics Plc (NASDAQ:AKTX) on Tuesday shared promising preclinical results for its experimental cancer treatment, AKTX-101.
The data highlights the therapy’s potential as a unique option for urothelial cancer, particularly in scenarios where currently available antibody-drug conjugates (ADCs) provide limited clinical benefits.
Addressing Unmet Needs In Oncology
AKTX-101 is a TROP2-directed ADC that leverages a proprietary PH1 RNA spliceosome-modulating payload.
According to the company, this novel mechanism addresses the emerging shortcomings of existing ADC payload categories, such as topoisomerase 1 and microtubule inhibitors.
Urothelial carcinoma represents a rapidly expanding market for ADC treatments, highlighted by the success of therapies like Padcev.
Despite these advancements, patients who experience a relapse after standard treatments face a severe lack of viable medical options.
Promising Preclinical Tumor Inhibition
During recent evaluations, AKTX-101 displayed meaningful anti-tumor efficacy across various clinically relevant models.
In the UM-UC-14 advanced urothelial carcinoma model—representing a metastatic setting where Padcev is a standard first-line option—AKTX-101 achieved statistically significant tumor growth inhibition, whereas Padcev showed limited effectiveness.
Furthermore, the experimental therapy demonstrated encouraging results against tumors that developed resistance to Trodelvy, a first-generation TROP2-directed ADC. When these resistant tumors were treated with AKTX-101, growth slowed significantly.
This suggests the PH1 payload’s ability to disrupt RNA splicing can overcome resistance linked to traditional Topoisomerase I payloads, potentially offering benefits for lung and breast cancers.
Future Clinical Milestones
Akari continues advancing IND-enabling processes for AKTX-101. The oncology biotechnology firm aims to launch a Phase 1 clinical trial by mid-2027 while simultaneously exploring further development opportunities for its PH1 payload platform to maximize its commercial potential.
AKTX Stock Price Activity: Akari Therapeutics shares were up 2.26% to $7.79 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock